http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
A Fast-Transient Repetitive Control Strategy for Programmable Harmonic Current Source
Lei, Wanjun,Nie, Cheng,Chen, Mingfeng,Wang, Huajia,Wang, Yue The Korean Institute of Power Electronics 2017 JOURNAL OF POWER ELECTRONICS Vol.17 No.1
The repetitive control (RC) strategy is widely used in AC power systems because of its high performance in tracking period signal and suppressing steady-state error. However, the dynamic response of RC is determined by the fundamental period delay $T_0$ existing in the internal model. In the current study, a ($nk{\pm}i$)-order harmonic RC structure is proposed to improve dynamic performance. The proposed structure has less data memory and can improve the tracking speed by n/2 times. $T_0$ proves the effectiveness of the ($nk{\pm}i$)-order RC strategy. The simulation and experiments of ($6k{\pm}1$)-order and ($4k{\pm}1$)-order RC strategy used in the voltage source inverter is conducted in this study to control the harmonic current source, which shows the validity and advantages of the proposed structure.
A Fast-Transient Repetitive Control Strategy for Programmable Harmonic Current Source
Wanjun Lei,Cheng Nie,Mingfeng Chen,Huajia Wang,Yue Wang 전력전자학회 2017 JOURNAL OF POWER ELECTRONICS Vol.17 No.1
The repetitive control (RC) strategy is widely used in AC power systems because of its high performance in tracking period signal and suppressing steady-state error. However, the dynamic response of RC is determined by the fundamental period delay T0 existing in the internal model. In the current study, a (nk ± i)-order harmonic RC structure is proposed to improve dynamic performance. The proposed structure has less data memory and can improve the tracking speed by n/2 times. T0 proves the effectiveness of the (nk ± i)-order RC strategy. The simulation and experiments of (6k ± 1)-order and (4k ± 1)-order RC strategy used in the voltage source inverter is conducted in this study to control the harmonic current source, which shows the validity and advantages of the proposed structure.
Rongxin Liao,Kehong Chen,Jinjin Li,Hengqiu He,Guangming Yi,Mingfeng Huang,Rongrong Chen,Lu Shen,Xiaoyue Zhang,Zaicheng Xu,Zhenzhou Yang,Yuan Peng 대한암학회 2023 Cancer Research and Treatment Vol.55 No.3
Purpose Oligometastatic non–small cell lung cancer (NSCLC) patients have been increasingly regarded as a distinct group that could benefit from local treatment to achieve a better clinical outcome. However, current definitions of oligometastasis are solely numerical, which are imprecise because of ignoring the biological heterogeneity caused by genomic characteristics. Our study aimed to profile the molecular alterations of oligometastatic NSCLC and elucidate its potential difference from polymetastasis. Materials and Methods We performed next-generation sequencing to analyze tumors and paired peripheral blood from 77 oligometastatic and 21 polymetastatic NSCLC patients to reveal their genomic characteristics and assess the genetic heterogeneity. Results We found ERBB2, ALK, MLL4, PIK3CB, and TOP2A were mutated at a significantly lower frequency in oligometastasis compared with polymetastasis. EGFR and KEAP1 alterations were mutually exclusive in oligometastatic group. More importantly, oligometastasis has a unique significant enrichment of apoptosis signaling pathway. In contrast to polymetastasis, a highly enriched COSMIC signature 4 and a special mutational process, COSMIC signature 14, were observed in the oligometastatic cohort. According to OncoKB database, 74.03% of oligometastatic NSCLC patients harbored at least one actionable alteration. The median tumor mutation burden of oligometastasis was 5.00 mutations/Mb, which was significantly associated with smoking, DNA damage repair genes, TP53 mutation, SMARCA4 mutation, LRP1B mutation, ABL1 mutation. Conclusion Our results shall help redefine oligometastasis beyond simple lesion enumeration that will ultimately improve the selection of patients with real oligometastatic state and optimize personalized cancer therapy for oligometastatic NSCLC.